Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Efficacy of Escitalopram in the Treatment of Internet Addiction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00565422
Recruitment Status : Completed
First Posted : November 30, 2007
Last Update Posted : May 28, 2008
Forest Laboratories
Information provided by:
Icahn School of Medicine at Mount Sinai

Brief Summary:
The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.

Condition or disease Intervention/treatment Phase
Internet Addiction Drug: Escitalopram Phase 4

Detailed Description:
Many individuals experience marked distress and functional impairments as a result of their perceived inability to control their 'non-essential' (non-job/school related) use of the Internet. Frequently these people develop a preoccupation with the Internet, a need for escape to the Internet, and increasing irritability when trying to cut back use of the Internet. There have been no studies to date looking at the effectiveness of medications in the treatment of this disorder. In our clinical experience, we find these patients with Internet addiction usually respond to serotonin reuptake inhibitors within 12 weeks. This study will examine the efficacy of escitalopram in Internet addiction among adults.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Escitalopram in the Treatment of Internet Addiction
Study Start Date : December 2002
Actual Study Completion Date : October 2004

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single Arm
Drug: Escitalopram
10 mg/day
Other Name: Lexapro

Primary Outcome Measures :
  1. length of non-essential Internet use in hours/week as well as CGI-Improvement [ Time Frame: baseline and biweekly for 10 weeks ]

Secondary Outcome Measures :
  1. ratings on depression, anxiety, impulsivity, self-esteem, obsessive-compulsive symptoms [ Time Frame: baseline and biweekly for 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject has signed an informed consent form
  2. Current diagnosis of Internet addiction
  3. Age ³ 18
  4. Subject must be able to take oral medication
  5. Subject may be in psychotherapy initiated at least three months prior to Screening. Subject must not discontinue or otherwise alter this therapy during the study.
  6. In the opinion of the investigator, the subject is capable of complying with all study procedures.

Exclusion Criteria:

  1. Current suicidal or homicidal ideation
  2. Subject has a primary diagnosis of schizophrenia or other psychotic disorders
  3. Subject has a primary diagnosis of Bipolar I disorder
  4. Current pedophilia
  5. Current DSM-IV diagnosis of substance dependence or abuse, excluding nicotine
  6. Women of child-bearing potential who are pregnant, nursing, or not using contraception
  7. Use of antidepressants at a therapeutic level for the treatment of problematic internet use within 2 weeks prior to study entry (or 4 weeks for use of MAOIs, or 6 weeks for use of fluoxetine)
  8. Current use of antidepressants at a therapeutic level for the treatment of a disorder other than problematic internet use
  9. Subject has any organic mental disorder
  10. Clinically significant unstable medical disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00565422

Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Forest Laboratories
Layout table for investigator information
Principal Investigator: Eric Hollander, MD Icahn School of Medicine at Mount Sinai

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Eric Hollander, Mount Sinai School of Medicine Identifier: NCT00565422    
Other Study ID Numbers: LXP-MD-09
First Posted: November 30, 2007    Key Record Dates
Last Update Posted: May 28, 2008
Last Verified: May 2008
Keywords provided by Icahn School of Medicine at Mount Sinai:
Internet addiction
Problematic internet use
Additional relevant MeSH terms:
Layout table for MeSH terms
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents